Frazier Life Sciences Management, L.P. 13F annual report
Frazier Life Sciences Management, L.P. is an investment fund managing more than $2.13 trillion ran by Steve Bailey. There are currently 48 companies in Mr. Bailey’s portfolio. The largest investments include Newamsterdam Pharma Company and Mirum Pharmaceuticals Inc, together worth $457 billion.
$2.13 trillion Assets Under Management (AUM)
As of 8th August 2024, Frazier Life Sciences Management, L.P.’s top holding is 12,226,943 shares of Newamsterdam Pharma Company currently worth over $235 billion and making up 11.0% of the portfolio value.
In addition, the fund holds 6,495,392 shares of Mirum Pharmaceuticals Inc worth $222 billion, whose value grew 43.2% in the past six months.
The third-largest holding is Krystal Biotech Inc worth $182 billion and the next is Hillevax Inc worth $154 billion, with 10,617,062 shares owned.
Currently, Frazier Life Sciences Management, L.P.'s portfolio is worth at least $2.13 trillion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Frazier Life Sciences Management, L.P.
The Frazier Life Sciences Management, L.P. office and employees reside in Palo Alto, California. According to the last 13-F report filed with the SEC, Steve Bailey serves as the Steve R. Bailey at Frazier Life Sciences Management, L.P..
Recent trades
In the most recent 13F filing, Frazier Life Sciences Management, L.P. revealed that it had opened a new position in
Erasca Inc and bought 16,216,216 shares worth $38.3 billion.
The investment fund also strengthened its position in Hillevax Inc by buying
835,590 additional shares.
This makes their stake in Hillevax Inc total 10,617,062 shares worth $154 billion.
On the other hand, there are companies that Frazier Life Sciences Management, L.P. is getting rid of from its portfolio.
Frazier Life Sciences Management, L.P. closed its position in Alpine Immune Sciences Inc on 15th August 2024.
It sold the previously owned 3,131,008 shares for $124 billion.
Steve Bailey also disclosed a decreased stake in Vaxcyte by approximately 0.1%.
This leaves the value of the investment at $78.5 billion and 1,039,405 shares.
One of the largest hedge funds
The two most similar investment funds to Frazier Life Sciences Management, L.P. are Etf Managers Group and Nicholas Hoffman ,. They manage $2.13 trillion and $2.13 trillion respectively.
Steve Bailey investment strategy
Frazier Life Sciences Management, L.P.’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 67.1% of
the total portfolio value.
The fund focuses on investments in the United States as
56.3% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
10% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $879 million.
The complete list of Frazier Life Sciences Management, L.P. trades based on 13F SEC filings
These positions were updated on August 15th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Newamsterdam Pharma Company |
No change
12,226,943
|
$234,879,575,000 | 11.01% |
| Mirum Pharmaceuticals Inc |
No change
6,495,392
|
$222,077,452,000 | 10.41% |
| Krystal Biotech Inc |
No change
988,460
|
$181,520,794,000 | 8.51% |
| Hillevax Inc |
8.54%
10,617,062
|
$153,522,717,000 | 7.20% |
| Alpine Immune Sciences Inc |
Closed
3,131,008
|
$124,113,157,000 | |
| Phathom Pharmaceuticals Inc |
No change
10,109,279
|
$104,125,574,000 | 4.88% |
| Rhythm Pharmaceuticals Inc. |
8.27%
2,371,304
|
$97,365,742,000 | 4.56% |
| BridgeBio Pharma Inc |
6.35%
3,632,604
|
$92,013,859,000 | 4.31% |
| Arcutis Biotherapeutics Inc |
No change
8,785,284
|
$81,703,141,000 | 3.83% |
| Disc Medicine Inc |
123.55%
1,754,834
|
$79,090,368,000 | 3.71% |
| Vaxcyte, Inc. |
8.78%
1,039,405
|
$78,485,472,000 | 3.68% |
| Edgewise Therapeutics Inc |
12.94%
3,731,067
|
$67,196,517,000 | 3.15% |
| AnaptysBio Inc |
140.70%
2,165,591
|
$54,269,710,000 | 2.54% |
| Apellis Pharmaceuticals Inc |
Closed
885,165
|
$52,029,999,000 | |
| Verona Pharma Plc |
9.95%
3,314,349
|
$47,925,487,000 | 2.25% |
| KalVista Pharmaceuticals Inc |
No change
3,687,867
|
$43,443,073,000 | 2.04% |
| Tarsus Pharmaceuticals, Inc. |
11.19%
1,587,527
|
$43,148,984,000 | 2.02% |
| Revolution Medicines Inc |
No change
997,455
|
$38,711,229,000 | 1.81% |
| Erasca Inc |
Opened
16,216,216
|
$38,270,270,000 | 1.79% |
| Agios Pharmaceuticals Inc |
66.67%
871,974
|
$37,599,519,000 | 1.76% |
| Soleno Therapeutics Inc |
No change
875,667
|
$35,727,214,000 | 1.67% |
| Aerovate Therapeutics Inc |
Closed
1,204,867
|
$35,627,917,000 | |
| Rocket Pharmaceuticals Inc |
No change
1,561,230
|
$33,613,282,000 | 1.58% |
| Savara Inc |
103.93%
8,157,385
|
$32,874,262,000 | 1.54% |
| Oric Pharmaceuticals, Inc. |
No change
4,142,855
|
$29,289,985,000 | 1.37% |
| Structure Therapeutics Inc |
Closed
629,194
|
$26,967,255,000 | |
| Cg Oncology Inc |
No change
770,000
|
$24,308,900,000 | 1.14% |
| Pepgen Inc |
No change
1,502,788
|
$23,984,496,000 | 1.12% |
| Deciphera Pharmaceuticals In |
Closed
1,455,837
|
$22,900,316,000 | |
| Merus N.V |
50.02%
373,100
|
$22,076,327,000 | 1.03% |
| Trevi Therapeutics, Inc. |
No change
7,381,090
|
$21,995,648,000 | 1.03% |
| Silence Therapeutics plc |
No change
1,148,591
|
$21,823,229,000 | 1.02% |
| Ultragenyx Pharmaceutical In |
Opened
425,000
|
$17,467,500,000 | 0.82% |
| Autolus Therapeutics plc |
No change
4,623,324
|
$16,089,168,000 | 0.75% |
| Cerevel Therapeutics Hldng I |
No change
393,000
|
$16,069,770,000 | 0.75% |
| Mereo BioPharma Group plc |
Opened
4,401,371
|
$15,844,936,000 | 0.74% |
| Adverum Biotechnologies Inc |
Closed
1,069,244
|
$15,119,110,000 | |
| Immatics N.v |
Opened
1,152,456
|
$13,391,539,000 | 0.63% |
| Tyra Biosciences Inc |
No change
832,220
|
$13,307,198,000 | 0.62% |
| Macrogenics Inc |
21.81%
3,010,727
|
$12,795,590,000 | 0.60% |
| Applied Therapeutics, Inc. |
17.07%
2,286,135
|
$10,676,250,000 | 0.50% |
| Puma Biotechnology Inc |
8.74%
3,062,558
|
$9,983,939,000 | 0.47% |
| 89bio Inc |
No change
1,000,000
|
$8,010,000,000 | 0.38% |
| Elevation Oncology Inc |
Opened
2,958,579
|
$7,988,163,000 | 0.37% |
| Cogent Biosciences, Inc. |
No change
936,576
|
$7,895,336,000 | 0.37% |
| Acadia Pharmaceuticals Inc |
No change
470,338
|
$7,642,993,000 | 0.36% |
| Arvinas Inc |
No change
285,331
|
$7,595,511,000 | 0.36% |
| Adverum Biotechnologies Inc |
Opened
1,069,244
|
$7,335,014,000 | 0.34% |
| Allogene Therapeutics Inc |
No change
2,867,750
|
$6,681,858,000 | 0.31% |
| Intellia Therapeutics Inc |
Closed
203,684
|
$5,603,347,000 | |
| An2 Therapeutics Inc |
50.40%
2,088,889
|
$4,491,111,000 | 0.21% |
| Design Therapeutics Inc |
Opened
1,195,179
|
$4,003,850,000 | 0.19% |
| Immunocore Hldgs Plc |
Opened
108,762
|
$3,685,944,000 | 0.17% |
| Gritstone Bio Inc |
Closed
1,030,878
|
$2,649,356,000 | |
| Bluebird bio Inc |
Closed
1,709,907
|
$2,188,681,000 | |
| Metagenomi Inc |
11.95%
245,692
|
$1,002,423,000 | 0.05% |
| Aclaris Therapeutics Inc |
No change
264,377
|
$290,815,000 | 0.01% |
| No transactions found | |||
| Showing first 500 out of 57 holdings | |||
Hedge funds similar to Frazier Life Sciences Management, L.P.
- Summit Partners Public Asset Management
- Capital International Ltd ca/
- Applied Finance Capital Management
- Fullerton Fund Management Co
- James Hambro & Partners
- Level Four Advisory Services
- Etf Managers Group
- Nicholas Hoffman ,
- Tweedy, Browne Co
- Cx Institutional
- Lake Street Advisors Group
- Northeast Investment Management
- Carlson Capital Management
- Laird Norton Wetherby Wealth Management